Hayward, a brief PubMed search using "membrane phospholipids (-PS)Alzheimers Disease" yielded several references that could bolster the concept of looking at anti-PS (or, better, anti-PE)therapy in that disease...and others. When I asked SK at ASHM what other diseases they were looking at for Bavi-, I don't think he pulled Alzheimer's at random from a basket of a gazillion diseases...
I haven't looked carefully at the latest in the anti-phospholipid syndrome tie-in, but hope to soon. Regards, and best wishes to all. This "quiet time" is a bit of a puzzle. It seems that at this point it would be clear from overall survival data whether the entire pooled NSCLC trial cohort (Bavi and placebo..whatever) survived longer than if they all had taken placebo...or all taken Bavi...or any combination. Simple math. I would think the company has moved on beyond incurable-staged disease at this point, but that should be reflected in the stock price. Let's face it. The MUST be a lot of people/companies who know the general efficacy picture.
Biochim Biophys Acta. 2010 Oct;1798(10):1969-76. Epub 2010 Jul 11.
Alzheimer's disease amyloid-beta peptide analogue alters the ps-dynamics of phospholipid membranes.
Buchsteiner A, Hauss T, Dante S, Dencher NA.
Aging Cell. 2012 Feb;11(1):63-72. doi: 10.1111/j.1474-9726.2011.00760.x. Epub 2011 Nov 28.
Alterations in phosphatidylethanolamine levels affect the generation of Aß.
Nesic I, Guix FX, Vennekens K, Michaki V, Van Veldhoven PP, Feiguin F, De Strooper B, Dotti CG, Wahle T.
Curr Alzheimer Res. 2011 Mar;8(2):213-21.
Neuronal membranes are key to the pathogenesis of Alzheimer's disease: the role of both raft and non-raft membrane domains.
Williamson R, Sutherland C.
